Second International Congress Drug Therapy in HIV Infection 18-22 November 1994 Glasgow, UK

TRANSMISSION OF 215 MUTANTS IN PRIMARY HIV INFECTION AND ANALYSIS AFTER 6 MONTHS OF ZIDOVUDINE

L. Perrin*, S. Yerly*, A. Rakik*, S. Kinloch* and B. Hirschel #
* Laboratory of Virology, # AIDS Center, Division of Infectious Diseases, Geneva University Hospital, 1211 Geneva 14, Switzerland

Int Cong Drug Therapy HIV 1994 Nov 18-22;2:Abstract No. 3.4
AIDS 1994, Vol. 8 (Suppl. 4);S3

Zidovudine is still the most frequently used antiviral drug and, as already reported, transmission of ZDV resistant viruses may occur. Several mutations affecting the reverse transcriptase gene have been identified; one of them affecting the 215 codon has been shown to be associated with high degree of resistance. Between 1989 and 1994, we have identified 60 patients with, primary HIV infection (PHI) in Geneva. We have determined, using selective PCR (1), the occurrence of transmission of 215 mutant isolates in these patients; 4 patients with 215 mutant virus have been identified: 0/5 in 1989, 1/10 en 1990, 0/11 in 1991, 1/10 in 1992. 2/10 in 1993 and 2/14 in 1994. All mutations have been confirmed by sequencing: 3 patients had a tyrosine instead of threonine and one a phenylalamine at position 215.

Twelve of these PHI patients have been treated with ZDV for 6 months (250 mg twice a day). At 6 months one patient with a 215 mutant isolate at initiation of therapy was still exhibit resistant virus, none of the 11 patients with '215 wild type developed 215 mutations.

These data suggest that, in the last 3 years, transmission of ZDV resistant isolates in Geneva occurred in around 10% of newly HIV infected patients.

(1) Larder BA et al., AIDS. 1991 Feb;5(2):137-44.

Presenting author: L. Perrin

1994-11-18
3.4

Originally published in AIDS Volume 8, Supplement 4 and hosted with permission of the publisher Lippincott Williams & Wilkins, 250 Waterloo Road, London, SE1 8RD, UK. Tel: +44 (0)20 7981 0700 Fax: +44 (0) 7981 0701

Copyright © 1994 - Lippincott Williams & Wilkins. All rights reserved. All abstracts from the 2nd International Congress Drug Therapy in HIV Infection, appearing on the AEGiS web site, are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, or otherwise published without the prior written permission of Lippincott Williams & Wilkins. You may not alter or remove any trademark, copyright or other notice. However, provided that you maintain all copyright and other notices contained therein, you may download material (one machine readable copy and one print copy per page) for your personal, non-commercial use only.

http://www.aidsonline.com http://www.ovid.com